相关实验视频

Updated: Jun 10, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

葡萄糖和葡萄糖样-1双激素治疗:可能的未来向脂肪脏疾病的可能未来

Mehmet Kanbay¹, Sidar Copur², Mustafa Guldan²

¹Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.

European journal of clinical investigation

|October 14, 2024

概括

双重激素治疗对管理与肥胖相关的脏疾病有前途. 这些针对葡萄糖类-1和葡萄糖受体的治疗方法可以改善功能并减缓慢性病的进展.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
内分泌学在内分泌学.
代谢疾病代谢疾病

背景情况:

肥胖影响发达国家40%的成年人,导致严重的健康问题,如糖尿病,脂肪肝疾病,心血管疾病和慢性病 (CKD).
目前的减肥药物治疗方法有限,这凸显了对新型治疗策略的需求.
内脏肥胖与代谢相关的脂肪肝疾病 (MAFLD) 和一种新发现的疾病 - - 脂肪脏有关,这两种疾病都对CKD的病理生理学有贡献.

研究的目的:

审查当前关于双重激素治疗的知识.
评估这些疗法在治疗脂肪和CKD方面的潜力.

主要方法:

这是对现有科学文献进行评价的叙述性综述.
专注于针对葡萄糖类-1 (GLP-1) 和葡萄糖受体的双重激素治疗.

主要成果:

类似葡萄糖素的-1激动剂和-葡萄糖共运输体-2抑制剂对结局有有益影响.
对于MAFLD的治疗,正在研究双重激动剂疗法,如survodutide和cotadutide.
脂肪脏是一种新兴的概念,与内脏肥胖相关的CKD.

结论:

新型降血糖药物,包括GLP-1激动剂和SGLT-2抑制剂,显示出改善结局的潜力.
针对GLP-1和葡萄糖素受体的双重激素治疗是一种有前途的途径,用于管理与肥胖相关的并发症.
对双重激动剂的进一步研究是有必要的,因为它们在控制脂肪和减缓CKD进展方面的作用.

关键词:

在糖尿病中,糖尿病是血糖类的.脂肪脏脂肪脏的情况葡萄糖是一种葡萄糖.类似于葡萄糖的-1-1 与代谢相关的脂肪肝疾病.

更多相关视频

A Model of Chronic Nutrient Infusion in the Rat

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...